Clinical Trials

Vibalogics, a global contract development and manufacturing organization (CDMO) that specializes in the production of virotherapy products, announced that it will manufacture additional clinical trial material for the lead COVID-19 vaccine candidate currently in development by the Janssen Pharmaceutical...

As the COVID-19 pandemic continues to limit movement all over the world, clinical trials have had to adapt by leveraging methodologies typically associated with hybrid or remote clinical trial designs. The alternative would be to suspend the trial and...

Humanigen, Inc., has dosed the first COVID-19 patient in its Phase III study for lenzilumab, its Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody. Catalent provides clinical supply support to Humanigen and its partners from its Philadelphia facility. “We...

Bioclinica has introduced a specialized program for the adjudication of adverse events that could result from COVID-19 infection. Bioclinica's new program provides an out-of-the-box Clinical Endpoint Committee solution. This solution combines world-class medical expertise, an experienced adjudication management team,...

Catalent, a global leader in clinical supply services, welcomed the news by Humanigen, Inc., that it has dosed the first COVID-19 patient in its previously announced Phase 3 study for lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating...

Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company has initiated Phase 3 clinical trials in India on Antiviral tablet Favipiravir, for which it received approval from India’s drug regulator DCGI in late April. Glenmark is the first company in...

CTI BioPharma Corp. initiated PRE-VENT, a Phase III study evaluating pacritinib in hospitalized patients with severe COVID-19. PRE-VENT, a randomized, double-blind, placebo-controlled study, will compare pacritinib plus standard of care (SOC) versus placebo plus standard of care in 358...